AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2013

Mar 13, 2013

30291_dirs_2013-03-13_9b7b2777-987b-43b9-8d90-20546a260396.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2013-03-13

Reporting Person: Mulligan Richard (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-03-13	Common Stock	S	2980	$174.7497	Disposed	9920	Direct
2013-03-13	Common Stock	S	5000	$175.7545	Disposed	4920	Direct

Footnotes

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.

F3: This represents the weighted average price for shares sold at a range between $174.23 (low) and $175.11 (high).

F4: This represents the weighted average price for shares sold at a range between $175.31 (low) and $175.98 (high).